TIL for the treatment of patients with solid cancer: an interactive workshop

TIL for the treatment of patients with solid cancer: an interactive workshop

Personalised T-cell therapy has now reached the solid tumour therapy field as a first of-its-kind immunotherapy for patients with melanoma with an approval granted by the FDA on February 17th, 2024.

Target

Experts from science, industry and authorities involved in development, regulation and marketing of TIL or other T-cell based (transgenic) therapeutic products. Physicians involved in cell-based immunotherapy and immunotherapy. Individuals involved in TIL manufacturing and other transgenic immune cell products. We aim to provide a nurturing environment for cross-fertilizing discussions in science, cell therapy development and regulatory requirements. 
 

Welcome to an inclusive, interactive TIL workshop in Lisbon 24/25 April!

Programme and Registration

> Access for students, academics and authorities is free.
> For Industry representatives, participation fee is € 200,00. 
 

To know more click here, to register click here.

Location

Champalimaud Foundation - Exhibition Hall
Avenida Brasília, 1400-038, Lisboa Portugal
Phone: + 351 210 480 200
www.fchampalimaud.org